| abstract |
The present invention addresses the problem of providing an antitumor agent for acute myeloid leukemia, the antitumor agent exhibiting practical effects on acute myeloid leukemia. According to the present invention, provided is an antitumor agent for acute myeloid leukemia, the antitumor agent containing a compound, such as (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)-4-pentyn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methyl-2-butenamide, represented by general formula [1] specified in the present specification, or a salt thereof, wherein the amount of the antitumor agent administered per dose is within a predetermined range. |